Losartan
- Generic Name
- Losartan
- Brand Names
- Hyzaar, Cozaar
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23ClN6O
- CAS Number
- 114798-26-4
- Unique Ingredient Identifier
- JMS50MPO89
- Background
Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Los...
- Indication
Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hyper...
- Associated Conditions
- Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
- Associated Therapies
- -
Influence of Aliskiren on Albuminuria After Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2015-05-18
- Lead Sponsor
- Medical University of Gdansk
- Target Recruit Count
- 18
- Registration Number
- NCT02446548
- Locations
- 🇵🇱
Medical University of Gdansk, Gdansk, Pomorskie, Poland
Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)
- Conditions
- Interventions
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2017-06-15
- Lead Sponsor
- Weill Cornell Medical College in Qatar
- Target Recruit Count
- 56
- Registration Number
- NCT02410005
- Locations
- 🇶🇦
Weill Cornell Medical College in Qatar, Doha, Qatar
🇶🇦Hamad Medical Corporation, Doha, Qatar
🇺🇸Weill Cornell Medical College, New York, New York, United States
Preventing Sickle Cell Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 1
- Registration Number
- NCT02373241
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Phase 1/2 Prospective Double-Blind Placebo-Controlled Randomized Clinical Trial of Losartan to Treat Grade II & III Hamstring Strains
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- James J. Irrgang
- Target Recruit Count
- 8
- Registration Number
- NCT02263729
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 179
- Registration Number
- NCT02248961
- Locations
- 🇷🇺
Moscow Health Department "City Clinical Hospital № 81", Moscow, Russian Federation
🇷🇺St. Petersburg State healthcare Institution "City Hospital number 28" "Maximilianovskaya", St. Petersburg, Russian Federation
🇷🇺St. Petersburg State Healthcare Institution 'Diagnostic Centre #85', St. Petersburg, Russian Federation
An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Arbor Pharmaceuticals, Inc.
- Target Recruit Count
- 215
- Registration Number
- NCT02235909
- Locations
- 🇧🇷
Fundação José Luiz Egydio Setúbal, São Paulo, Brazil
🇺🇸Pioneer Clinical Research, North Miami, Florida, United States
🇺🇸Georgia Clinical Research, Snellville, Georgia, United States
Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT02232763
- Locations
- 🇰🇷
Seoul National University Children's Hospital, Seoul, Korea, Republic of
Efficacy and Safety of Losartan in Children With Ig A Nephropathy
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT02232776
- Locations
- 🇰🇷
Seoul National University Children's Hospital, Seoul, Korea, Republic of
Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Chen Xiangmei
- Target Recruit Count
- 1600
- Registration Number
- NCT02231125
- Locations
- 🇨🇳
Guang An Men Hospital China Academy of Chinese Medical Sciences, Beijing, Beijing, China
🇨🇳Jilin Province People's Hospital, Changchun, Jilin, China
🇨🇳Ningxia Hui Autonomous Region's Hospital, Yinchuan, Ningxia, China
Residual Renal Function Preservation in Peritoneal Dialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2014-08-01
- Target Recruit Count
- 96
- Registration Number
- NCT02190318
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.